3 Canadian Biotech Stocks Trading Below Fair Value By Up To 93%

AI driven drug discovery is back in the spotlight after Iambic Therapeutics raised $150m in its Nasdaq IPO, reminding investors how quickly a single medical breakthrough can reshape expectations. Canadian biotech stocks sit right on that fault line between high risk and potentially outsized payoff. This article picks out 3 of the better balanced names from our biotech screener that could merit a closer look.

The three stocks highlighted below are just a starting sample from this biotech idea. The full screen surfaced 6 more companies with equally interesting stories that are not covered here. If you want to identify, analyze, and focus on your highest conviction setups, head straight into the Biotech Stocks screener.

Bright Minds Biosciences (CNSX:DRUG)

Bright Minds Biosciences focuses on biotech drug development, building a pipeline of serotonin targeting therapies such as BMB-101 and other 5 HT2/5 HT2C candidates for severe neurological and neuropsychiatric disorders. The company is pre commercial and has a market value of about CA$737 million.

Bright Minds Biosciences provides direct exposure to high risk, high potential biotech work on serotonin based treatments for epilepsy and rare neuropsychiatric conditions, with BMB-101 already in Phase 2. Attractive value signals and recent analyst interest are characteristic of a biotech profile that depends on how one crucial clinical readout develops.

That all hinges on whether the potential payoff justifies the clinical risk, so it is worth reading the 2 key rewards and 3 important warning signs (2 are major!) before the next data point hits.

Cronos Group (TSX:CRON)

Cronos Group is a cannabinoid-focused business built around cannabis cultivation and formulation, generating about US$179 million from cannabis and cannabis-derived products, including branded oils, edibles, vapes, and tinctures, and carries a market value near CA$1.7 billion.

Cronos Group gives you direct exposure to cannabinoid science within this biotech screen, with its brands and formulations tying R&D work to real-world products on shelves and in clinics.

Expanded access to high-growth international medical cannabis markets, such as Israel, Germany, and Switzerland, positions Cronos to benefit from ongoing regulatory reforms and rising global acceptance of cannabinoid-based wellness products, boosting both top-line revenue and long-term market diversification.

What happens to Cronos Group’s margin story if one pressure point on its cost base shifts faster than the product mix evolves?

If that margin tension has your attention, read the full narrative for Cronos Group to see how Cronos Group’s product mix, cash position and optionality could be quietly decoupling.

Green Thumb Industries (CNSX:GTII)

Green Thumb Industries leans into the biotech theme through its THC and CBD product portfolio, with about US$846 million from retail stores and roughly US$681 million from consumer packaged cannabis goods in 2025, backed by a roughly CA$2.0b market value.

For biotech investors looking at cannabinoid-based products, Green Thumb Industries offers a different angle on therapeutics, with medical and adult-use brands sitting inside a sizeable US retail footprint and a capital return story that now matters almost as much as store openings.

Although Green Thumb Industries highlights disciplined capital allocation and has authorized an additional US$50 million share repurchase on top of roughly US$200 million already spent, rising SG&A that reached US$118 million or 38% of revenue in Q2 2026 raises the risk that future buybacks are funded alongside a structurally higher cost base.

The real swing factor is whether one quiet shift in the cost structure ultimately supports richer margins or gradually eats away at that biotech-style upside.

If you want to see whether that cost shift is quietly masking or accelerating Green Thumb Industries’ edge, go straight to the full narrative for Green Thumb Industries for the full picture.

Seeking Alternatives Beyond Biotech Picks

Fresh breakout stories do not sit around waiting. Momentum shifts, under the radar for now, can be identified quickly once the crowd wakes up, so act now.

• Explore potential future cash generators by scanning the 3 dividend fortresses before yields change and the most attractive opportunities draw increased attention from faster investors.
• Look for possible infrastructure leaders by reviewing the 43 power grid technology and infrastructure stocks while these grid and electrification companies may still be getting limited coverage.
• Consider real-world automation themes by checking the curated 90 robotics and automation stocks before momentum-focused traders increase activity in this area.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com